Clinical Trial: Effectiveness, Safety, and Tolerability of Darunavir/cobicistat Plus Lamivudine Versus Darunavir/cobicistat Plus Tenofovir/emtricitabine in Virologically Suppressed HIV-1-positive Individuals: 48-week Follow-up in Mexico

U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06907056) titled 'Effectiveness, Safety, and Tolerability of Darunavir/cobicistat Plus Lamivudine Versus Darunavir/cobicistat Plus Tenofovir/emtricitabine in Virologically Suppressed HIV-1-positive Individuals: 48-week Follow-up in Mexico' on March 26.

Brief Summary: Unicenter, open-label, randomized, noninferiority trial included men with HIV-1 RNA levels 50 copies/ml after 48 weeks of follow-up according to the snapshot algorithm, with a non-inferiority margin of up to 10%. For statistical analysis, data distribution will be identified using the Kolmogorov-Smirnov test; categorical data will be analyzed using the X2 or Fisher test, as appropriate, ...